Toxicology and Disease/Cancer Therapy in Reactive Oxygen Species-Mediated Drugs and TreatmentsView this Special Issue
Research Article | Open Access
Bin Huang, Kuo-Hao Chiang, Hsin-Su Yu, Ying-Lun Chen, Huey-Ling You, Wei-Ting Liao, "Arsenic Modulates Posttranslational S-Nitrosylation and Translational Proteome in Keratinocytes", The Scientific World Journal, vol. 2014, Article ID 360153, 7 pages, 2014. https://doi.org/10.1155/2014/360153
Arsenic Modulates Posttranslational S-Nitrosylation and Translational Proteome in Keratinocytes
Arsenic is a class I human carcinogen (such as inducing skin cancer) by its prominent chemical interaction with protein thio (-SH) group. Therefore, arsenic may compromise protein S-nitrosylation by competing the -SH binding activity. In the present study, we aimed to understand the influence of arsenic on protein S-nitrosylation and the following proteomic changes. By using primary human skin keratinocyte, we found that arsenic treatment decreased the level of protein S-nitrosylation. This was coincident to the decent expressions of endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS). By using LC-MS/MS, around twenty S-nitrosoproteins were detected in the biotin-switched eluent. With the interest that arsenic not only regulates posttranslational S-nitrosylation but also separately affects protein’s translation expression, we performed two-dimensional gel electrophoresis and found that 8 proteins were significantly decreased during arsenic treatment. Whether these decreased proteins are the consequence of protein S-nitrosylation will be further investigated. Taken together, these results provide a finding that arsenic can deplete the binding activity of NO and therefore reduce protein S-nitrosylation.
Protein S-nitrosylation, the covalent attachment of nitric oxide (NO) to protein thio (-SH) group, is an important posttranslational modification that affects a wide variety of proteins for cellular signaling in normal physiology and a broad spectrum of human diseases [1, 2]. S-nitrosylation signaling controls a number of cellular processes, such as protein-protein interactions , nuclear transcriptions , and membrane-associated proteins activation [5, 6]. Pathophysiology is correlated with hypo- or hyper-S-nitrosylation of specific protein targets rather than a general cellular insult due to not only the loss of or enhanced nitric oxide synthase activity but also the denitrosylation by a major denitrosylase, S-nitrosoglutathione reductase (GSNOR) . Abnormal protein S-nitrosylation causes many diseases such as cardiovascular, musculoskeletal, and neurological dysfunction . Furthermore, autophagy, a vacuolar degradation for long-lived and aggregate-prone proteins, plays an important role in neurodegeneration. Inhibition of autophagy by S-nitrosylation results in stress-mediated protein aggregation in neurodegenerative diseases [8, 9].
S-nitrosylation is also associated with cancer . Potential mechanisms of S-nitrosylation in carcinogenesis are focused on apoptosis and DNA repair . Survival of tumor cell could be induced by inactivation of proapoptotic signaling or activation of antiapoptotic pathways . Inhibition of caspase protease by protein nitrosylation promotes extended survival of malignant cells . For example, nitrosylation of caspase 9 inhibits the mitochondrial pathway of apoptosis in cholangiocarcinoma cell line . Additionally, p53 induces apoptotic cell death and causes cell cycle arrest in response to various stresses . S-nitrosylation of p53 suppresses p53-mediated apoptosis in colon carcinogenesis . Bcl-2, a major anti-apoptotic regulatory protein, was regulated by S-nitrosylation in various carcinoma tissues [11, 17, 18]. S-nitrosylation is shown to modulate the activity, stability, and cellular localization of key DNA repair proteins, including O(6)-alkylguanine-DNA-alkyltransferase (AGT), 8-oxoguanine glycosylase (Ogg1), apurinic-apyrimidinic endonuclease 1 (APE1), and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) . Inactivation of AGT by S-nitrosylation is found in hepatocarcinogenesis . Moreover, S-nitrosylated APE1 export from the nucleus to the cytoplasm is described in colon adenomas, breast cancer, and hepatocellular carcinomas . Also, S-nitrosylated DNA-PKcs shows increased transcriptional expression and activity in HEK-293 .
It is well known that arsenic, a human carcinogen, showed its chemical carcinogenesis activity by interaction with protein -SH groups. By its -SH binding activity, therefore, arsenic may compromise protein S-nitrosylations in cells. In addition, it is reported that arsenic has a significant effect on NO production in the endothelium . Arsenic remains one of the most concerned environmental toxicants, which has been classified as a group I human carcinogen by the International Agency for Research on Cancer (IARC). Epidemiological studies demonstrated that long-term exposure to inorganic arsenic through either ingestion or inhalation is associated with an increased risk of malignant cancers in the urinary bladder, lung, and especially skin, since arsenic tends to concentrate in keratinocytes . However, the role of S-nitrosylation induced by arsenic in skin carcinogenesis remains unclear. In the present study, we hypothesize that arsenic can alter protein S-nitrosylation and NO production in skin keratinocyte. Our contribution is identifying interactions between arsenic and S-nitrosylation axis in keratinocytes that can provide the novel molecular and pharmacological strategies for potential clinical applications.
2. Materials and Methods
2.1. Human Keratinocyte Culture
Freshly obtained prepuce specimens were used to cultivate the primary human cultured keratinocytes. Briefly, normal human prepuce specimens were washed with PBS, then cut into small pieces, and incubated in medium containing 0.25% trypsin overnight at 4°C. The epidermal sheet was lifted from the dermis using a fine forceps. The epidermal cells were pelleted by centrifugation (500 ×g, 10 min) and dispersed into individual cells by repeated aspiration with a pipette. Isolated keratinocytes must be cultured in commercialized keratinocyte serum free medium (Invitrogen, Carlsbad, USA) at 37°C in a humidified incubator with 5% CO2 atmosphere with or without sodium arsenite (Sigma, St. Louis, USA) treatment (10 μM). This primary keratinocyte culture protocol using human skin samples has been approved by Institutional Review Board of Kaohsiung Medical University Hospital (KMUH-IRB-960119).
2.2. Cell Lysis and Proteins Extraction
Keratinocytes after treatment were washed with cord buffer [NaCl (0.14 M), KCl (4 mM), glucose (11 mM), and HEPES (10 mM, pH 7.4)] and then lysed with 100 μL of lysis buffer [Hepes (250 mM, pH 7.7), EDTA (1 mM), neocuproine (0.1 mM), and CHAPS (0.4%, w/v)]. After centrifugation, protein supernatant is collected and protein concentrations are determined with BCA assay reagent (Thermo Fisher Scientific Inc, Rockford, IL, USA).
2.3. Biotin Switch Method for Purifying S-Nitrosoproteins
The biotin switch method was used according to previous study [22, 25]. Cells were washed with 1 × cord buffer (10 mM HEPES, pH 7.4, 0.14 M NaCl, 4 mM KCl, and 11 mM glucose). Protein lysates were obtained using ultrasound and lysis buffer (250 mM HEPES, pH 7.7, 1 mM EDTA, 0.1 mM neocuproine, and 0.4% (w/v) CHAPS). The free thiols were methylated with blocking buffer (225 mM HEPES, pH 7.7, 0.9 mM EDTA, 0.09 mM neocuproine, 2.5% (w/v) SDS, and 20 mM MMTS) at the ratio of 0.8 mg/1 mL and were incubated at 50°C for 20 min with agitation. To remove residual MMTS, the MMTS-treated lysate was precipitated with cold acetone and the resulting pellet was resuspended in HENS buffer (250 mM HEPES, pH 7.7, 1 mM EDTA, 0.1 mM neocuproine, and 1% (w/v) SDS). This was followed by addition of one-third of the HENS suspension’s final volume of 4 mM N-[6-(biotinamido) hexyl]-3′-(2′-pyridyldithio) propionamide (biotin-HPDP/DMF) mixed with 1 mM ascorbate. The protein lysate/biotin-HPDP mixture was incubated at room temperature for 1 hour to allow biotinylation to occur. These mixtures were precipitated with cold acetone to remove excess biotin-HPDP and then resuspended in HENS buffer. The biotinylated proteins (i.e., the former S-nitrosoproteins) were recovered using neutravidin-agarose beads (15 μL/per mg of initiated protein input) in neutralization buffer (20 mM HEPES, pH 7.7, 100 mM NaCl, 1 mM EDTA, and 0.5% (v/v) Triton X-100). The agarose beads were rinsed with washing buffer (20 mM HEPES, pH 7.7, 600 mM NaCl, 1mMEDTA, and 0.5% (v/v) Triton X-100). The biotinylated proteins were eluted by elution buffer (20 mM HEPES, pH 7.7, 100 mM NaCl, 1 mM EDTA, and 100 mM 2-ME). We added 100 femtomole of BSA in the eluent as a standard in the subsequent MS/MS analysis. The salt and detergent in eluents were removed by SpinOUT and DetergentOUT resins (Geno Technology Inc., MO, USA).
2.4. Mass Spectrometric Assay
Around 100 ng eluents were reduced, alkylated, and trypsin digested according to the user’s guideline (In-Gel Tryptic Digestion Kit, Thermo Fisher Scientific, IL, USA). The peptide lysates were further desalting with Proteomics C18 Column (Mass solution Ltd., Taipei, Taiwan) and then subjected to mass analysis by nLC/Q-TOF tandem mass spectrometry (Micromass, Manchester, UK). MS data were searched for against the NCBI database using an in-house MASCOT search program (Matrix Science, London, UK). Search parameters were set as mass values: monoisotopic, protein mass: unrestricted, peptide mass tolerance: ±0.4 Da, fragment mass tolerance: ±0.4 Da, max missed cleavages: 1, and the instrument type: ESI-QUAD-TOF.
2.5. Western Blot Analysis
Forty micrograms of cell lysates with various treatments was mixed with equal volume of sample buffer [Tris-HCl (62.5 mM, pH6.8), SDS (3%, w/v), 2-mercaptoethanol (5%, v/v), and glycerol (10%, v/v)] and then separated by SDS-PAGE. The gel was transferred to PVDF membranes (Millipore, MA, USA) and immunoblotted with antibodies: eNOS (1 : 3000, Cell Signaling Tech. MA, USA), iNOS (1 : 3000, Cell Signaling Tech. MA, USA). The membranes were visualized with the SuperSignal West Femto reagent (Thermo Fisher Scientific, IL, USA) on X-ray films. The images on X-ray films were scanned using a digital scanner (Microtek International Inc.) and the density was calculated by the Progenesis Samespots v2.0 software (NonLinear Dynamics, Newcastle, UK).
2.6. Two-Dimensional Gel Electrophoresis
Extracted protein (1 mg) was precipitated with 3 volumes of cold acetone at −20°C for at least 20 min. After centrifugation, the protein pellets were air-dried for 5 min, dissolved in sample buffer [9 M urea, 2% (w/v) CHAPS, 60 mM DTT, and 2% (v/v, pH 4–7) IPG buffer (GE Healthcare BioSci., NJ, USA)], and incubated for at least 30 min to denature proteins completely. The protein solution was mixed with rehydration solution [8 M urea, 2% (w/v) CHAPS, and 0.5% (v/v, pH 4–7) IPG buffer] to reach a final volume of 340 μL and then soaked into an 18 cm DryStrip (pH 4–7, GE Healthcare BioSci.) for up to 12 h on Ettan IPGphor system (GE Healthcare BioSci.). Isoelectric focusing (IEF) was performed with the accumulated voltage set to 32 kVh. After IEF analysis, stripped gels were equilibrated with trisbuffer [50 mM Tris-HCl, pH 8.8, containing 2% (w/v) SDS, 6 M urea, 30% (v/v) glycerol, and 60 mM DL-dithiothreitol (DTT)] for 20 min. The stripped gels were then alkylated in the same buffer containing 135 mM iodoacetic acid for additional 20 min. The equilibrated IEF strip was laid on the top of a vertical SDS-PAGE system to perform the 2-DE.
2.7. Image Analysis
The gels were stained with VisPRO dye (Visual Protein Biotech., Taipei, Taiwan) and scanned with a digital scanner (Microtek International Inc.). The translational levels were calculated by ImageMaster software (GE Healthcare BioSci.). The gel slices excised from the silver-stained gel were digested with trypsin for 4 hours at 37°C (In-Gel Tryptic Digestion Kit, Thermo Fisher Scientific Inc.) and then subjected to mass spectrometric analysis.
3. Results and Discussion
3.1. Arsenic Reduces Protein S-Nitrosylation
Biotin switch is now the most popular methodology for identifying S-nitrosoproteins in various tissues . In the present study, the procedure of biotin switch was simply indicated (Figure 1(a)). By treatment with 10 μM of arsenic for 1 hour, at least three groups of protein S-nitrosylation were significantly decreased in keratinocytes (Figure 1(b)). These biotinylated proteins, that is, NO-bound S-nitrosylated proteins, were purified from streptavidin conjugated agarose and then analyzed by LC-MS/MS. Totally, 20 and 13 S-nitrosoproteins were separately identified in the control and arsenic treatments. This was coincident to the decreased NO production and the reduced S-nitrosylated proteins.
3.2. Arsenic Decreases the Expressions of eNOS and iNOS
It has been reported that NO in keratinocytes was produced through the activation of eNOS and iNOS . Therefore, in the present study, we examined the expressions of both enzymes in the existence of arsenic. As shown in Figures 2(a) and 2(b), the significant decreases of their expressions were observed.
3.3. Arsenic Modulates Translational Proteome in Keratinocytes
In addition to elucidating those posttranslational S-nitrosylated proteins, we further investigated the proteins changed in their expression levels. By using 2-DE, 8 proteins showed a dramatic decrease in the expression level (Figures 3(a) and 3(b)). These identified proteins are annotated function in (Table 1). More specifically, HNRNPK is a pre-mRNA-binding protein, which has been identified to be involved in arsenic-induced apoptosis in acute myeloid leukemia cells . PSMD13 is proteasome protein regulating the degradation of ubiquitinated proteins, which has been identified in fetal fibroblasts from glutathione deficient mouse using arsenic-induced apoptosis model by cDNA microarray . RPLP0 is a ribosomal protein, in general conditions, constantly expressed in cells (house-keeping gene). The functional interactions between arsenic and RPLP0 required further investigations. CTSD is a protease active in intracellular protein breakdown. Increased CTSD has been identified in arsenic-treated human lymphoblastoid cell lines correlated with autophagy . However, here, we found arsenic treatment decreased CTSD in human keratinocytes. NDUFS3 is a subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I). Decreased NDUFS3 has been identified in hepatoma cell line . Indeed, our previous study has identified the dose response between arsenic and NDUFS3 in human keratinocytes. Low concentrations (0.1–1.0 μM) of arsenic increased NDUFS3 associated with keratinocyte proliferation. High concentration (5.0 μM) of arsenic decreased NDUFS3 correlated with cell death . This decreased NDUFS3 was represented in our current data. ECHS1 is a catalytic enzyme in mitochondrial fatty acid betaoxidation pathway; however, direct evidence between ECHS1 and arsenic is not yet clarified. To summarize, from our proteomic data, altered apoptosis and mitochondrial metabolic functions were the dominant effects of arsenic on human keratinocytes.
|Function of the protein obtained via the MASCOT software (http://www.matrixscience.com) search program by querying the NCBI database. The parameters were set at peptide mass tolerance ±0.4 Da and allowed missed cleavage 1.|
bAccession number from NCSI database.
cTheoretic protein molecular weight and pI annotated in NCBI database.
dExperimental protein molecular weight and pI calculated from 2-DE gel.
In the current study, we concluded that arsenic can compete with nitric oxide in binding cysteine residues so that the protein S-nitrosylation is inhibited. Whether the decreased S-nitrosylation is correlated to arsenic-induced pathology attracts a great attention in the further study. In addition, the homeostasis of cellular apoptosis and mitochondrial dysfunctions is worthy of further study.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
The authors thank Dr. Hans-Uwe Dahms for critical reading of the paper. This study was supported by a grant from the National Science Council (NSC100-2314-B-037-053 and NSC101-2320-B-037-041). They are grateful to the Center for Resources, Research & Development of Kaohsiung Medical School for the support of fluorescent imaging.
- M. W. Foster, D. T. Hess, and J. S. Stamler, “Protein S-nitrosylation in health and disease: a current perspective,” Trends in Molecular Medicine, vol. 15, no. 9, pp. 391–404, 2009.
- D. T. Hess, A. Matsumoto, S. O. Kim, H. E. Marshall, and J. S. Stamler, “Protein S-nitrosylation: purview and parameters,” Nature Reviews Molecular Cell Biology, vol. 6, no. 2, pp. 150–166, 2005.
- N. V. Marozkina and B. Gaston, “S-Nitrosylation signaling regulates cellular protein interactions,” Biochimica et Biophysica Acta: General Subjects, vol. 1820, no. 6, pp. 722–729, 2012.
- H. E. Marshall and J. S. Stamler, “Inhibition of NF-κB by S-nitrosylation,” Biochemistry, vol. 40, no. 6, pp. 1688–1693, 2001.
- W. Kim, Y. Choi, P. V. Rayudu et al., “Attenuation of NMDA receptor activity and neurotoxicity by nitroxyl anion, NO-,” Neuron, vol. 24, no. 2, pp. 461–469, 1999.
- S. A. Lipton, Y. B. Choi, Z. H. Pan et al., “A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds,” Nature, vol. 364, no. 6438, pp. 626–632, 1993.
- T. Nakamura and S. A. Lipton, “Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases,” Cell Death and Differentiation, vol. 18, no. 9, pp. 1478–1486, 2011.
- S. Sarkar, V. I. Korolchuk, M. Renna et al., “Complex inhibitory effects of nitric oxide on autophagy,” Molecular Cell, vol. 43, no. 1, pp. 19–32, 2011.
- S. M. Haldar and J. S. Stamler, “S-Nitrosylation at the interface of autophagy and disease,” Molecular Cell, vol. 43, no. 1, pp. 1–3, 2011.
- E. Aranda, C. López-Pedrera, J. R. de la Haba-Rodríguez, and A. Rodríguez-Ariza, “Nitric oxide and cancer: the emerging role of S-nitrosylation,” Current Molecular Medicine, vol. 12, no. 1, pp. 50–67, 2011.
- A. K. Iyer, N. Azad, L. Wang, and Y. Rojanasakul, “Role of S-nitrosylation in apoptosis resistance and carcinogenesis,” Nitric Oxide, vol. 19, no. 2, pp. 146–151, 2008.
- S. Ghavami, M. Hashemi, S. R. Ande et al., “Apoptosis and cancer: mutations within caspase genes,” Journal of Medical Genetics, vol. 46, no. 8, pp. 497–510, 2009.
- J. B. Mannick, A. Hausladen, L. Liu et al., “Fas-induced caspase denitrosylation,” Science, vol. 284, no. 5414, pp. 651–654, 1999.
- N. J. Török, H. Higuchi, S. Bronk, and G. J. Gores, “Nitric oxide inhibits apoptosis downstream of cytochrome c release by nitrosylating caspase 9,” Cancer Research, vol. 62, no. 6, pp. 1648–1653, 2002.
- A. Vazquez, E. E. Bond, A. J. Levine, and G. L. Bond, “The genetics of the p53 pathway, apoptosis and cancer therapy,” Nature Reviews Drug Discovery, vol. 7, no. 12, pp. 979–987, 2008.
- J. L. Williams, P. Ji, N. Ouyang, L. Kopelovich, and B. Rigas, “Protein nitration and nitrosylation by NO-donating aspirin in colon cancer cells: Relevance to its mechanism of action,” Experimental Cell Research, vol. 317, no. 10, pp. 1359–1367, 2011.
- N. Azad, V. Vallyathan, L. Wang et al., “S-nitrosylation of Bcl-2 inhibits its ubiquitin-proteasomal degradation: a novel antiapoptotic mechanism that suppresses apoptosis,” The Journal of Biological Chemistry, vol. 281, no. 45, pp. 34124–34134, 2006.
- P. Chanvorachote, U. Nimmannit, C. Stehlik et al., “Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination,” Cancer Research, vol. 66, no. 12, pp. 6353–6360, 2006.
- W. Xu, L. Liu, G. C. M. Smith, and L. G. Charles, “Nitric oxide upregulates expression of DNA-PKcs to protect cells from DNA-damaging anti-tumour agents,” Nature Cell Biology, vol. 2, no. 6, pp. 339–345, 2000.
- W. Wei, B. Li, M. A. Hanes, S. Kakar, X. Chen, and L. Liu, “S-nitrosylation from GSNOR deficiency impairs DNA repair and promotes hepatocarcinogenesis,” Science Translational Medicine, vol. 2, no. 19, Article ID 19ra13, 2010.
- J. Jones Larry E., L. Ying, A. B. Hofseth et al., “Differential effects of reactive nitrogen species on DNA base excision repair initiated by the alkyladenine DNA glycosylase,” Carcinogenesis, vol. 30, no. 12, pp. 2123–2129, 2009.
- M. T. Forrester, J. W. Thompson, M. W. Foster, L. Nogueira, M. A. Moseley, and J. S. Stamler, “Proteomic analysis of S-nitrosylation and denitrosylation by resin-assisted capture,” Nature Biotechnology, vol. 27, no. 6, pp. 557–559, 2009.
- Y. Kumagai and J. Pi, “Molecular basis for arsenic-induced alteration in nitric oxide production and oxidative stress: implication of endothelial dysfunction,” Toxicology and Applied Pharmacology, vol. 198, no. 3, pp. 450–457, 2004.
- C. J. Chen, Y. C. Chuang, T. M. Lin, and H. Y. Wu, “Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers,” Cancer Research, vol. 45, no. 11, pp. 5895–5899, 1985.
- B. Huang, C. L. Liao, Y. P. Lin, S. C. Chen, and D. L. Wang, “S-nitrosoproteome in endothelial cells revealed by a modified biotin switch approach coupled with western blot-based two-dimensional gel electrophoresis,” Journal of Proteome Research, vol. 8, no. 10, pp. 4835–4843, 2009.
- F. Gao, Y. Wu, M. Zhao, C. Liu, L. Wang, and G. Chen, “Protein Kinase C-delta mediates down-regulation of heterogeneous nuclear ribonucleoprotein K protein: involvement in apoptosis induction,” Experimental Cell Research, vol. 315, no. 19, pp. 3250–3258, 2009.
- S. Kann, C. Estes, J. F. Reichard et al., “Butylhydroquinone protects cells genetically deficient in glutathione biosynthesis from arsenite-induced apoptosis without significantly changing their prooxidant status,” Toxicological Sciences, vol. 87, no. 2, pp. 365–384, 2005.
- A. M. Bolt, R. M. Douglas, and W. T. Klimecki, “Arsenite exposure in human lymphoblastoid cell lines induces autophagy and coordinated induction of lysosomal genes,” Toxicology Letters, vol. 199, no. 2, pp. 153–159, 2010.
- D. R. Yoo, S. A. Chong, and M. J. Nam, “Proteome profiling of arsenic trioxide-treated human hepatic cancer cells,” Cancer Genomics and Proteomics, vol. 6, no. 5, pp. 269–274, 2009.
- C. Lee, S. Wu, C. Hong et al., “Aberrant cell proliferation by enhanced mitochondrial biogenesis via mtTFA in arsenical skin cancers,” The American Journal of Pathology, vol. 178, no. 5, pp. 2066–2076, 2011.
Copyright © 2014 Bin Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.